Laflunimus 13C3, 15N

[13C3, 15N]-Laflunimus is a chemical compound that belongs to the class of immunosuppressive drugs. It is a modified form of the drug Laflunimus that has been labeled with isotopes of carbon and nitrogen. The labeling is done for research purposes to study the pharmacokinetics and pharmacodynamics of the drug. Laflunimus is used in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. It works by inhibiting the production of inflammatory cytokines and reducing the activity of immune cells. [13C3, 15N]-Laflunimus is used in preclinical studies to investigate the mechanisms of action of Laflunimus and its metabolites. The isotopic labeling of [13C3, 15N]-Laflunimus allows for the use of advanced analytical techniques such as mass spectrometry to track the drug's distribution and metabolism in the body. This information is useful in determining the optimal dosing regimen for the drug and identifying potential drug interactions. In terms of chemical information, [13C3, 15N]-Laflunimus has a molecular weight of 341.4 g/mol and a chemical formula of C14H6N3O4[13C3, 15N]. It has a half-life of approximately 18 hours and is eliminated primarily through the feces. Overall, [13C3, 15N]-Laflunimus is a valuable tool in the preclinical development of Laflunimus and other immunosuppressive drugs. Its isotopic labeling allows for precise tracking and analysis of the drug's pharmacokinetics and pharmacodynamics, providing valuable insights into its efficacy and safety.